Response Evaluation Criteria in Solid Tumors
"Response Evaluation Criteria in Solid Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Descriptor ID |
D066066
|
| MeSH Number(s) |
E01.789.800.379 N04.761.559.590.800.569 N05.715.360.575.575.800.569
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Response Evaluation Criteria in Solid Tumors".
Below are MeSH descriptors whose meaning is more specific than "Response Evaluation Criteria in Solid Tumors".
This graph shows the total number of publications written about "Response Evaluation Criteria in Solid Tumors" by people in this website by year, and whether "Response Evaluation Criteria in Solid Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 2 | 2 |
| 2017 | 1 | 7 | 8 |
| 2018 | 1 | 14 | 15 |
| 2019 | 1 | 8 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Response Evaluation Criteria in Solid Tumors" by people in Profiles.
-
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
-
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019 09; 119:151-157.
-
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019 10; 20(10):1386-1394.
-
The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 2019 07; 16(7):442-458.
-
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. J Thorac Oncol. 2019 10; 14(10):1794-1806.
-
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019 06; 153(3):535-540.
-
Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results. Cardiovasc Intervent Radiol. 2019 Jun; 42(6):853-862.
-
Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. Eur J Cancer. 2019 03; 109:196-203.
-
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019 Mar; 13(2):199-204.
-
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019 01; 20(1):134-144.